DelveInsight

View All

latest-pharma-news-and-updates-for-eli-lilly-novartis-janssen-ipsen-kite
Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval

FDA Approves Eli Lilly’s Jaypirca for Relapsed Mantle Cell Lymphoma Eli Lilly has received FDA approval for Jaypirca, a non-covalent BTK inhibitor, in relapsed mantle cell lymphoma (MCL) patients who have relapsed after treatment with other drugs in the class. Adult MCL patients who have previously received at l...

Find More

pharma-news
Eli Lilly’s COVID-19 Antibody trial; Approval for Oriahnn; Gilead’s Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19

Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV555.  LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, COVID-19 has taken the lives of more than 372,000 people g...

Find More

DelveInsight Logo
Introducing a new brand identity, and a new website: DelveInsight.

Today we’re unveiling a new identity and launching a new logo.  For any company, to get a new logo designed might look like a cakewalk; however, it is exactly the opposite. This is a big deal because we are highly recognized by our old one in our industry, among our clients, employees, business partners, an...

Find More

Cholera vaccine delivered; Rice-inspired breakthroughs; International partnerships

Cholera vaccine delivered through a cup of rice water Vaccinations against prevalent pathogens could be ingested as oral or inhaled as nasal vaccines, this is due to the development of non-invasive vaccines, which target the mucous membranes. These could help fight a plethora of infectious diseases such as cholera,...

Find More

acute myeloid leukemia
Predicting risk of Acute Myeloid Leukemia (AML) in healthy individuals

The occurrence of acute myeloid leukemia (AML) keeps on increasing with age and mortality surpasses 90% if diagnosed after age of 65. Most cases emerge with no perceivable early side effects and patients generally give the intense intricacies of bone marrow failure. The beginning of such oinitial acute myeloid leuke...

Find More

transthyretin amyloidosis
Notizia

Arming antibiotics with a vaccination-like immune response Harnessing the ability of the body’s immune system has already well-tried to be effective in treating cancer. Marcos Pires, Ph.D., a Lehigh associate professor of biochemistry performed a test on it. To make it worse, these microorganism perpetually evolv...

Find More


enzymes FAAH
Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential

Fatty acid amide hydrolase (FAAH) belongs to the serine hydrolase family of enzymes. The identification of this enzyme was led by the discovery and characterization of fatty acid amides, including anandamide and oleamide, as a fundamental class of endogenous signaling molecules. FAAH serves as the major metabolic re...

Find More

hepatic encephalopathy
Hepatic Encephalopathy- An ailment of liver to brain

Hepatic Encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-standing or chronic liver disorder are at high risk. The disease may also be triggered by bleeding in the digestive tract,...

Find More

Delveinsight
NF-κB Inhibitors- A Promising Future

NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a protein transcription factor that can orchestrate complex biological processes such as cell survival, cytokine production, inflammatory response and cellular responses. NF-κB is also involved in producing the synergistic immune responses. NF...

Find More